SUTRO BIOPHARMA INC's ticker is STRO and the CUSIP is 869367102. A total of 114 filers reported holding SUTRO BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $642,644 | -60.5% | 185,200 | -47.0% | 0.00% | -50.0% |
| Q2 2023 | $1,626,105 | -16.5% | 349,700 | -17.0% | 0.00% | -20.0% |
| Q1 2023 | $1,946,406 | -37.1% | 421,300 | +10.0% | 0.01% | -44.4% |
| Q4 2022 | $3,095,448 | +60.5% | 383,100 | +10.2% | 0.01% | +50.0% |
| Q3 2022 | $1,929,000 | +42.2% | 347,500 | +33.4% | 0.01% | +50.0% |
| Q2 2022 | $1,357,000 | +54.4% | 260,500 | +143.7% | 0.00% | +100.0% |
| Q1 2022 | $879,000 | -37.3% | 106,900 | +13.4% | 0.00% | -50.0% |
| Q4 2021 | $1,403,000 | -51.9% | 94,300 | -38.9% | 0.00% | -50.0% |
| Q3 2021 | $2,915,000 | +70.5% | 154,300 | +67.7% | 0.01% | +60.0% |
| Q2 2021 | $1,710,000 | +25.6% | 92,000 | +53.8% | 0.01% | +25.0% |
| Q1 2021 | $1,361,000 | +46.2% | 59,800 | +39.4% | 0.00% | +100.0% |
| Q4 2020 | $931,000 | +121.7% | 42,900 | +2.6% | 0.00% | +100.0% |
| Q3 2020 | $420,000 | – | 41,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,675,579 | $5,814,259 | 1.78% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,883,693 | $20,416,415 | 1.10% |
| Kynam Capital Management, LP | 1,552,675 | $5,387,782 | 0.88% |
| Parkman Healthcare Partners LLC | 1,182,168 | $4,102,123 | 0.75% |
| Rubric Capital Management LP | 3,344,810 | $11,606,491 | 0.44% |
| BVF INC/IL | 3,347,946 | $11,617,373 | 0.31% |
| DAFNA Capital Management LLC | 283,079 | $982,284 | 0.31% |
| SECTORAL ASSET MANAGEMENT INC | 432,339 | $1,500,216 | 0.29% |
| Eversept Partners, LP | 769,638 | $2,670,644 | 0.23% |
| Frazier Life Sciences Management, L.P. | 780,000 | $2,706,600 | 0.18% |